セッション詳細
[O2]Oral Presentations 2
2026年7月7日(火) 11:00 〜 11:49
伊藤謝恩ホール(伊藤国際学術研究センターB2)
座長:浦木 隆太、高 鵬
[O2-01]Differential regulation of macropinocytosis and motility by the EhRacM–EhGEFM signaling axis in Entamoeba histolytica
Misato Shimoyama1, Kumiko Nakada-Tsukui1, *Tomo Nozaki1 (1. Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo (Japan))
[O2-02]Interventions for protozoan parasites
*Cevayir Coban1 (1. IMSUT, UTOPIA, The University of Tokyo (Japan))
[O2-03]核酸免疫学と１粒子生物学から新たなDTVデザインへ
*KEN J ISHII1,2,3 (1. The Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo (Japan), 2. International Vaccine Design Center (VDESC), IMSUT (Japan), 3. UTOPIA, The University of Tokyo (Japan))
[O2-04]Acute Fasting Attenuates Vaccine Efficacy
*Ryuta URAKI1, Yoshihiro Kawaoka2,3,4 (1. Department of GMP Education and Immunovirology, The UTOPIA Center, The University of Tokyo (Japan), 2. Department of Virology, The UTOPIA Center, The University of Tokyo (Japan), 3. The Research Center for Global Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security (Japan), 4. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison (USA))
[O2-05]日本におけるRSV母体免疫ワクチンおよび抗体製剤の費用対効果
*Noriko Kitamura1, Motoi Suzuki1, Kaja Abbas2 (1. Center for Infectious Disease Epidemiology, NIID, JIHS (Japan), 2. Department of Infectious Disease Dynamics, Institute of Tropical Medicine, Nagasaki University (Japan))
[O2-06]Jet injection-mediated combination adjuvant potentiates naked mRNA vaccines against infectious diseases
*Nan Qiao1,4, Junichi Ishikawa1,4, Fumihiko Yasui2, Kaori Sano3, Satoshi Uchida1,4 (1. Department of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo (Japan), 2. Research Center for Infectious Diseases Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo (Japan), 3. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo (Japan), 4. Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki (Japan))
[O2-07]Innovative mucosal adjuvant development using heat-killed Escherichia coli
*Peng Gao1, Naoki Morita1, Genta Furuya1, Keishu Takahashi1, Mizuki Yamamoto2, Ryuta Uraki3,4,5, Maki Kiso3,4, Mutsumi Ito3,4, Hideo Negishi6, Chiaki Tomimoto7, Mizuho Wakayama7, Ken J. Ishii6, Yoshihiro Kawaoka3,4, Reiko Shinkura1 (1. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo (Japan), 2. Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan (Japan), 3. Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan (Japan), 4. Division of Virology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan (Japan), 5. The Research Center for Global Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. (Japan), 7. Noster Inc (Japan))